Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.

Trial Profile

Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Diabetic nephropathies; Diabetic retinopathy; Proteinuria
  • Focus Registrational; Therapeutic Use
  • Acronyms DIRECT; DIRECT-Protect-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jul 2021 Results (N=1575) post hoc analysis from two randomized controlled trials, DIRECT-Protect 1 and 2 assessing candesartan on progression of diabetic retinopathy in type 1 and type 2 diabetes published in the Diabetic Medicine
    • 29 Jun 2021 Results of post-hoc analysis assessing the effect of candesartan on the progression of diabetic retinopathy in 783 and 792 randomly chosen subjects from two randomized controlled trials (DIRECT-Protect 1 and DIRECT-Protect 2), presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 24 Sep 2010 Results of an analysis that examined the effects of treatment on microalbuminuria presented at the 46th Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top